{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:15:32Z","timestamp":1793121332833,"version":"4.5.0"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Samjinpharm Co., Ltd","award":["SJ-IIT-22-10"],"award-info":[{"award-number":["SJ-IIT-22-10"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"\n Background<\/jats:title>\n Although new preventive treatments for migraine have emerged, it remains essential to validate the efficacy of established drugs to ensure broader therapeutic options for migraine and, in particular, for vestibular migraine where clinical evidence is more limited. This study aimed to assess the therapeutic effectiveness of nimodipine, an L-type calcium channel blocker, in patients with migraine and vestibular migraine, with reference to outcomes observed with topiramate.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Using a prospective open-label study involving nine referral-based university hospitals in South Korea, we recruited 850 patients (81% women, mean age\u2009\u00b1\u2009SD\u2009=\u200941\u2009\u00b1\u200912) with migraine, including 255 with vestibular migraine. The primary outcome was the change in headache days over three months. The secondary outcomes included changes in pain rating scale, Migraine Disability Assessment Scale (MIDAS) and Headache Impact Test-6 (HIT-6). The outcomes of vestibular migraine included dizziness days and intensity, Dizziness Handicap Inventory, and UCLA-Dizziness Questionnaire.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of the 850 patients, 465 (55%) completed three months of evaluation (205 in the nimodipine group, 160 in the topiramate group, and 100 in the combination group). All groups showed a significant reduction in the headache days (1.2\u20132 days\/week,\n p<\/jats:italic>\n \u2009<\u20090.001) without inter-group differences (\n p<\/jats:italic>\n \u2009=\u20090.865). The topiramate group showed greater improvements in MIDAS and HIT-6 scores than the nimodipine (\n p<\/jats:italic>\n \u2009=\u20090.004) and combination groups (\n p<\/jats:italic>\n \u2009=\u20090.040). For vestibular migraine (n\u2009=\u2009131), all groups improved in headache and dizziness outcomes (\n p<\/jats:italic>\n \u2009<\u20090.001) without inter-group differences. Adverse events leading to study discontinuation were observed only in 14 (2%) patients without a difference among the groups.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n Nimodipine was associated with improvements in headache-related outcomes in migraine and in both headache- and dizziness-related outcomes in vestibular migraine.\n Given the observed improvements and favorable tolerability,<\/jats:bold>\n nimodipine may be a valuable treatment option for migraine and vestibular migrain.\n <\/jats:p>\n \n Trial registration<\/jats:bold>\n <\/jats:p>\n cris.nih.go.kr (KCT0010555).<\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pone.0344948","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:30:57Z","timestamp":1773941457000},"page":"e0344948","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic efficacy of nimodipine and topiramate on migraine and vestibular migraine; A prospective multicenter open-label study"],"prefix":"10.1371","volume":"21","author":[{"given":"Seo-Young","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Young","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Ah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u2011Yun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Hwan","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Hye","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Yoon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Hae","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Han","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Myung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang-Dong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1508-2024","authenticated-orcid":true,"given":"Ji-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"issue":"19","key":"pone.0344948.ref001","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1056\/NEJMra1915327","article-title":"Migraine","volume":"383","author":"M Ashina","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0344948.ref002","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s10194-023-01567-4","article-title":"Future targets for migraine treatment beyond CGRP","volume":"24","author":"L Al-Hassany","year":"2023","journal-title":"J Headache Pain"},{"issue":"7","key":"pone.0344948.ref003","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/head.14153","article-title":"The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice","volume":"61","author":"Board of Directors of the American Headache Society","year":"2021","journal-title":"Headache"},{"issue":"6","key":"pone.0344948.ref004","doi-asserted-by":"crossref","first-page":"3331024231183166","DOI":"10.1177\/03331024231183166","article-title":"The effect of blood pressure lowering medications on the prevention of episodic migraine: A systematic review and meta-analysis","volume":"43","author":"C Carcel","year":"2023","journal-title":"Cephalalgia"},{"issue":"1","key":"pone.0344948.ref005","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s10194-023-01657-3","article-title":"European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention-part 2: flunarizine","volume":"24","author":"CI Deligianni","year":"2023","journal-title":"J Headache Pain"},{"issue":"5","key":"pone.0344948.ref006","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/jnc.15792","article-title":"Nimodipine accelerates the restoration of functional hyperemia during spreading oligemia","volume":"168","author":"\u00c1 Menyh\u00e1rt","year":"2024","journal-title":"J Neurochem"},{"issue":"1","key":"pone.0344948.ref007","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/1570159X17666190927113021","article-title":"Nimodipine Reappraised: An Old Drug With a Future","volume":"18","author":"AP Carlson","year":"2020","journal-title":"Curr Neuropharmacol"},{"issue":"6","key":"pone.0344948.ref008","first-page":"393","article-title":"Effect of a fixed combination of nimodipine and betahistine versus betahistine as monotherapy in the long-term treatment of M\u00e9ni\u00e8re\u2019s disease: a 10-year experience","volume":"32","author":"D Monzani","year":"2012","journal-title":"Acta Otorhinolaryngol Ital"},{"issue":"3","key":"pone.0344948.ref009","first-page":"135","article-title":"Nimodipine in otolaryngology: from past evidence to clinical perspectives","volume":"35","author":"D Monzani","year":"2015","journal-title":"Acta Otorhinolaryngol Ital"},{"issue":"2","key":"pone.0344948.ref010","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/WNO.0000000000000791","article-title":"Vestibular migraine: how to sort it out and what to do about it","volume":"39","author":"SC Beh","year":"2019","journal-title":"J Neuroophthalmol"},{"issue":"1","key":"pone.0344948.ref011","doi-asserted-by":"crossref","first-page":"20","DOI":"10.21790\/rvs.2024.024","article-title":"Preventive medical treatment of vestibular migraine: a practical review","volume":"24","author":"JH Choi","year":"2025","journal-title":"Res Vestib Sci"},{"issue":"11","key":"pone.0344948.ref012","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1093\/brain\/awac264","article-title":"Vestibular migraine treatment: a comprehensive practical review","volume":"145","author":"D Smyth","year":"2022","journal-title":"Brain"},{"issue":"8","key":"pone.0344948.ref013","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/jama.291.8.965","article-title":"Topiramate for migraine prevention: a randomized controlled trial","volume":"291","author":"JL Brandes","year":"2004","journal-title":"JAMA"},{"issue":"17","key":"pone.0344948.ref014","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","article-title":"Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society","volume":"78","author":"SD Silberstein","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"pone.0344948.ref015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/head.14069","article-title":"Systematic review of outcomes and endpoints in preventive migraine clinical trials","volume":"61","author":"JS McGinley","year":"2021","journal-title":"Headache"},{"issue":"4","key":"pone.0344948.ref016","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jclinepi.2005.05.010","article-title":"Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test","volume":"59","author":"RR Coeytaux","year":"2006","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"pone.0344948.ref017","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1001\/archotol.1990.01870040046011","article-title":"The development of the Dizziness Handicap Inventory","volume":"116","author":"GP Jacobson","year":"1990","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"1","key":"pone.0344948.ref018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache classification committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"issue":"1","key":"pone.0344948.ref019","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s10194-023-01671-5","article-title":"European Headache Federation (EHF) critical reappraisal and meta-analysis of oral drugs in migraine prevention - part 3: topiramate","volume":"24","author":"B Raffaelli","year":"2023","journal-title":"J Headache Pain"},{"issue":"1","key":"pone.0344948.ref020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1526-4610.2009.01496.x","article-title":"Clinical assessment of topiramate therapy in patients with migrainous vertigo","volume":"50","author":"S Gode","year":"2010","journal-title":"Headache"},{"key":"pone.0344948.ref021","article-title":"Canadian Headache Society guideline for migraine prophylaxis","volume":"39","author":"T Pringsheim","year":"2012","journal-title":"Can J Neurol Sci"},{"issue":"4","key":"pone.0344948.ref022","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1526-4610.1988.hed2804260.x","article-title":"Effect of prophylactic administration of nimodipine in patients with migraine","volume":"28","author":"DJ Stewart","year":"1988","journal-title":"Headache"},{"issue":"3","key":"pone.0344948.ref023","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1526-4610.1983.hed2303106.x","article-title":"Nimodipine, a new calcium antagonist, in the prophylactic treatment of migraine","volume":"23","author":"HJ Gelmers","year":"1983","journal-title":"Headache"},{"issue":"6","key":"pone.0344948.ref024","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1526-4610.1983.hed2306266.x","article-title":"Clinical effectiveness of calcium entry blockers in prophylactic treatment of migraine and cluster headaches","volume":"23","author":"JS Meyer","year":"1983","journal-title":"Headache"},{"issue":"10","key":"pone.0344948.ref025","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1526-4610.1989.hed2910639.x","article-title":"European Multicenter Trial of Nimodipine in the Prophylaxis of Classic Migraine (Migraine With Aura)","volume":"29","year":"1989","journal-title":"Headache"},{"issue":"10","key":"pone.0344948.ref026","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1526-4610.1989.hed2910633.x","article-title":"European Multicenter Trial of Nimodipine in the Prophylaxis of Common Migraine (Migraine Without Aura)","volume":"29","year":"1989","journal-title":"Headache"},{"key":"pone.0344948.ref027","article-title":"Flunarizine in the treatment of vestibular vertigo: experimental and clinical data","author":"R Schmidt","year":"1991","journal-title":"J Cardiovasc Pharmacol"},{"key":"pone.0344948.ref028","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1749-6632.1988.tb33414.x","article-title":"Calcium entry blockers in the treatment of vertigo","volume":"522","author":"J Olesen","year":"1988","journal-title":"Ann N Y Acad Sci"},{"issue":"11","key":"pone.0344948.ref029","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1007\/s00405-013-2786-4","article-title":"Flunarizine in the prophylaxis of migrainous vertigo: a randomized controlled trial","volume":"271","author":"A Lepcha","year":"2014","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"pone.0344948.ref030","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fneur.2017.00524","article-title":"The Efficacy of Venlafaxine, Flunarizine, and Valproic Acid in the Prophylaxis of Vestibular Migraine","volume":"8","author":"F Liu","year":"2017","journal-title":"Front Neurol"},{"issue":"4","key":"pone.0344948.ref031","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s00405-020-05802-5","article-title":"Analysis of the effectiveness of the prophylaxis of vestibular migraine depending on the diagnostic category and the prescribed drug","volume":"277","author":"E Dom\u00ednguez-Dur\u00e1n","year":"2020","journal-title":"Eur Arch Otorhinolaryngol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0344948","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:31:02Z","timestamp":1773941462000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0344948"}},"subtitle":[],"editor":[{"given":"Jeyasakthy","family":"Saniasiaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0344948","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]}}}